Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global antihyperlipidemic drugs market reached a value of US$ 11.31 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 15.81 Billion by 2027, exhibiting a CAGR of 5.20% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient’s cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

 

 
 

www.imarcgroup.com

Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, route of administration and distribution channel.

Breakup by Drug Class:

 

 
 

www.imarcgroup.com

Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others
     

Breakup by Route of Administration:

  • Oral
  • Intravenous
     

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers
     

Breakup by Region:

 

 
 

www.imarcgroup.com

To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Drug Class, Route of Administration, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Antihyperlipidemic Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Drug Class
    6.1    Statins
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Bile Acid Sequestrants
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Cholesterol Absorption Inhibitors
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Fibric Acid Derivatives
        6.4.1 Market Trends
        6.4.2 Market Forecast
    6.5    PCSK9 Inhibitors
        6.5.1 Market Trends
        6.5.2 Market Forecast
    6.6    Combination
        6.6.1 Market Trends
        6.6.2 Market Forecast
    6.7    Others
        6.7.1 Market Trends
        6.7.2 Market Forecast
7    Market Breakup by Route of Administration
    7.1    Oral
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Intravenous
        7.2.1 Market Trends
        7.2.2 Market Forecast
8    Market Breakup by Distribution Channel
    8.1    Hospital Pharmacies
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Retail Stores
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Online Retailers
        8.3.1 Market Trends
        8.3.2 Market Forecast
9    Market Breakup by Region
    9.1    North America
        9.1.1 United States
           9.1.1.1 Market Trends
           9.1.1.2 Market Forecast
        9.1.2 Canada
           9.1.2.1 Market Trends
           9.1.2.2 Market Forecast
    9.2    Asia-Pacific
        9.2.1 China
           9.2.1.1 Market Trends
           9.2.1.2 Market Forecast
        9.2.2 Japan
           9.2.2.1 Market Trends
           9.2.2.2 Market Forecast
        9.2.3 India
           9.2.3.1 Market Trends
           9.2.3.2 Market Forecast
        9.2.4 South Korea
           9.2.4.1 Market Trends
           9.2.4.2 Market Forecast
        9.2.5 Australia
           9.2.5.1 Market Trends
           9.2.5.2 Market Forecast
        9.2.6 Indonesia
           9.2.6.1 Market Trends
           9.2.6.2 Market Forecast
        9.2.7 Others
           9.2.7.1 Market Trends
           9.2.7.2 Market Forecast
    9.3    Europe
        9.3.1 Germany
           9.3.1.1 Market Trends
           9.3.1.2 Market Forecast
        9.3.2 France
           9.3.2.1 Market Trends
           9.3.2.2 Market Forecast
        9.3.3 United Kingdom
           9.3.3.1 Market Trends
           9.3.3.2 Market Forecast
        9.3.4 Italy
           9.3.4.1 Market Trends
           9.3.4.2 Market Forecast
        9.3.5 Spain
           9.3.5.1 Market Trends
           9.3.5.2 Market Forecast
        9.3.6 Russia
           9.3.6.1 Market Trends
           9.3.6.2 Market Forecast
        9.3.7 Others
           9.3.7.1 Market Trends
           9.3.7.2 Market Forecast
    9.4    Latin America
        9.4.1 Brazil
           9.4.1.1 Market Trends
           9.4.1.2 Market Forecast
        9.4.2 Mexico
           9.4.2.1 Market Trends
           9.4.2.2 Market Forecast
        9.4.3 Others
           9.4.3.1 Market Trends
           9.4.3.2 Market Forecast
    9.5    Middle East and Africa
        9.5.1 Market Trends
        9.5.2 Market Breakup by Country
        9.5.3 Market Forecast
10    SWOT Analysis
    10.1    Overview
    10.2    Strengths
    10.3    Weaknesses
    10.4    Opportunities
    10.5    Threats
11    Value Chain Analysis
12    Porters Five Forces Analysis

    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13    Price Analysis
14    Competitive Landscape

    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    Amgen Inc.
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio
           14.3.1.3 Financials
        14.3.2    AstraZeneca plc
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio
           14.3.2.3 Financials
           14.3.2.4 SWOT Analysis
        14.3.3    Daiichi Sankyo Company Limited
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio
           14.3.3.3 Financials
           14.3.3.4 SWOT Analysis
        14.3.4    Merck & Co. Inc.
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio
           14.3.4.3 Financials
        14.3.5    Novartis AG
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio
           14.3.5.3 Financials
           14.3.5.4 SWOT Analysis
        14.3.6    Pfizer Inc.
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio
           14.3.6.3 Financials
        14.3.7    Sanofi S.A
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio
           14.3.7.3 Financials

List of Figures

Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2021
Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2021
Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2021
Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2021
Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2022-2027
Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
Table 7: Global: Antihyperlipidemic Drugs Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

The global antihyperlipidemic drugs market was valued at US$ 11.31 Billion in 2021.

We expect the global antihyperlipidemic drugs market to exhibit a CAGR of 5.20% during 2022-2027.

The growing usage of antihyperlipidemic drugs to aid in lowering the serum levels of cholesterol and various lipids in the blood is primarily driving the global antihyperlipidemic drugs market.

The sudden outbreak of the COVID-19 pandemic has led to the rising demand for antihyperlipidemic drugs to treat the onset of coronary artery disease among the patients, which is an adverse side-effect of the coronavirus disease.

Based on the drug class, the global antihyperlipidemic drugs market has been segmented into statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, PCSK9 inhibitors, combination, and others. Currently, statins hold the majority of the total market share.

Based on the distribution channel, the global antihyperlipidemic drugs market can be divided into hospital pharmacies, retail stores, and online retailers. Among these, hospital pharmacies exhibit a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global antihyperlipidemic drugs market include Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi S.A.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links